FI106385B - Förfaranden för att producera protein C - Google Patents

Förfaranden för att producera protein C Download PDF

Info

Publication number
FI106385B
FI106385B FI945877A FI945877A FI106385B FI 106385 B FI106385 B FI 106385B FI 945877 A FI945877 A FI 945877A FI 945877 A FI945877 A FI 945877A FI 106385 B FI106385 B FI 106385B
Authority
FI
Finland
Prior art keywords
protein
cell line
human
adenovirus
cells
Prior art date
Application number
FI945877A
Other languages
English (en)
Finnish (fi)
Other versions
FI945877A (sv
FI945877A0 (sv
Inventor
Brian William Grinnell
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of FI945877A0 publication Critical patent/FI945877A0/sv
Publication of FI945877A publication Critical patent/FI945877A/sv
Application granted granted Critical
Publication of FI106385B publication Critical patent/FI106385B/sv

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6464Protein C (3.4.21.69)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21069Protein C activated (3.4.21.69)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells
    • C12N2510/02Cells for production
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00Culture process characterised by temperature

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (10)

1. Förfarande för ökning av produktionen av protein C i en med adenovirus transformerad rekombinanta ) 5 däggdjursvärdcell, kännetecknat av att i nämn-da förfarande odlas nämnda med denovirus transformerade rekombinanta däggdjursvärdcell vid en temperatur pä ca 38 - 39 °C.
2. Förfarande enligt patentkrav 1, k ä n n e -10 tecknat av att den rekombinanta däggdjursvärdcellen är en 293-cell.
3. Förfarande enligt patentkrav 1, k ä n n e -tecknat av att inkuberingstemperaturen är cirka 3 8 °C. 15
4. Förfarande enligt patentkrav 1, k ä n n e - tecknat av att inkuberingstemperaturen är cirka 3 9 °C.
5. Förfarande enligt patentkrav 2, kanne -tecknat av att inkuberingstemperaturen är cirka 20 38 °C.
6. Förfarande enligt patentkrav 2, kanne -tecknat av att inkuberingstemperaturen är cirka 38,5 °C.
7. Förfarande enligt patentkrav 2, k ä n n e - .. 25 tecknat av att inkuberingstemperaturen är cirka 3 9 °C.
8. Förfarande för ökning av gammakarboxylations-graden hos en pä rekombinant sätt producerad protein C-molekyl, kännetecknat av att i nämnda förfa- 30 rande odlas nämnda pä rekombinant sätt producerade protein ; C-molekyl i en rekombinant AV12-värdcell vid en temperatur pä cirka 38 - 39 °C.
9. Förfarande enligt patentkrav 8,känne- v tecknat av att den rekombinanta AV12-värdcellen od- 35 las vid cirka 38 °C. 106385
10. Förfarande enligt patentkrav 8, kanne -tecknat av att den rekombinanta AV12-värdcellen od-las vid cirka 39 °C. ^ 1 < • ·
FI945877A 1993-12-15 1994-12-14 Förfaranden för att producera protein C FI106385B (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/168,035 US5618714A (en) 1993-12-15 1993-12-15 Methods for producing protein C
US16803593 1993-12-15

Publications (3)

Publication Number Publication Date
FI945877A0 FI945877A0 (sv) 1994-12-14
FI945877A FI945877A (sv) 1995-06-16
FI106385B true FI106385B (sv) 2001-01-31

Family

ID=22609820

Family Applications (1)

Application Number Title Priority Date Filing Date
FI945877A FI106385B (sv) 1993-12-15 1994-12-14 Förfaranden för att producera protein C

Country Status (28)

Country Link
US (1) US5618714A (sv)
EP (1) EP0658626B1 (sv)
JP (1) JP3662614B2 (sv)
KR (1) KR950018454A (sv)
CN (1) CN1107887A (sv)
AT (1) ATE196165T1 (sv)
AU (1) AU687914B2 (sv)
BR (1) BR9404991A (sv)
CA (1) CA2138101A1 (sv)
CO (1) CO4340654A1 (sv)
CZ (2) CZ315794A3 (sv)
DE (1) DE69425809T2 (sv)
DK (1) DK0658626T3 (sv)
ES (1) ES2149244T3 (sv)
FI (1) FI106385B (sv)
GR (1) GR3034909T3 (sv)
HU (1) HU219508B (sv)
IL (1) IL111983A0 (sv)
NO (1) NO944846L (sv)
NZ (1) NZ270140A (sv)
PE (1) PE42695A1 (sv)
PL (1) PL176381B1 (sv)
PT (1) PT658626E (sv)
RU (1) RU2110574C1 (sv)
SI (1) SI0658626T1 (sv)
UA (1) UA26870C2 (sv)
YU (1) YU73494A (sv)
ZA (1) ZA949981B (sv)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19724543A1 (de) * 1997-06-11 1998-12-17 Philips Patentverwaltung Wechsler-Gerät für Informationsplatten
WO2002069232A2 (en) 2001-02-19 2002-09-06 Merck Patent Gmbh Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
AU2003226012B2 (en) 2002-03-29 2007-05-24 Merck Sharp & Dohme Corp. Methods of virus production
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
EP1773371A4 (en) * 2004-07-23 2009-12-30 Univ Rochester ACTIVATED PROTEIN C INHIBITS SIDE EFFECTS OF PLASMINOGEN ACTIVATOR IN THE BRAIN
WO2006136033A1 (en) * 2005-06-23 2006-12-28 The University Of British Columbia Coagulation factor iii polymorphisms associated with prediction of subject outcome and response to therapy
WO2007140625A1 (en) * 2006-06-09 2007-12-13 The University Of British Columbia Interferon gamma polymorphisms as indicators of subject outcome in critically ill subjects
WO2009089620A1 (en) * 2008-01-15 2009-07-23 The Universityof British Columbia Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4959318A (en) * 1985-06-27 1990-09-25 Zymogenetics, Inc. Expression of protein C
US4968626A (en) * 1985-08-15 1990-11-06 Board Of Reagents Of The University Of Washington DNA sequence coding for protein C
EP0245949B1 (en) * 1986-04-09 1997-10-29 Eli Lilly And Company A method of using eukaryotic expression vectors comprising the bk virus enhancer
EP0289586A4 (en) * 1986-11-17 1990-04-10 New England Medical Ct INCREASING GAMMA CARBOXYLATION OF RECOMBINANT, VITAMIN K-DEPENDENT PROTEINS.
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
ZA889497B (en) * 1987-12-28 1990-08-29 Lilly Co Eli Vectors and compounds for expression of zymogen forms of human protein c
JPH0246296A (ja) * 1988-08-09 1990-02-15 Hoechst Japan Ltd 雑種プロテインc及びその製造方法
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
CA1332049C (en) * 1988-10-07 1994-09-20 Eli Lilly And Company Eukaryotic expression
ES2047946T3 (es) * 1989-08-11 1994-03-01 Zymogenetics Inc Metodos de cultivos celulares para producir proteina c activada.
IL97312A (en) * 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
AU1180692A (en) * 1991-01-29 1992-08-27 Teijin Limited Human protein c expression vector

Also Published As

Publication number Publication date
FI945877A (sv) 1995-06-16
AU8045294A (en) 1995-06-22
UA26870C2 (uk) 1999-12-29
HU219508B (hu) 2001-04-28
FI945877A0 (sv) 1994-12-14
CZ290724B6 (cs) 2002-10-16
HU9403600D0 (en) 1995-02-28
CZ315794A3 (en) 1995-10-18
HUT69979A (en) 1995-09-28
EP0658626A1 (en) 1995-06-21
IL111983A0 (en) 1995-03-15
DE69425809D1 (de) 2000-10-12
EP0658626B1 (en) 2000-09-06
JPH07222589A (ja) 1995-08-22
RU2110574C1 (ru) 1998-05-10
PE42695A1 (es) 1995-12-12
AU687914B2 (en) 1998-03-05
DE69425809T2 (de) 2001-02-01
KR950018454A (ko) 1995-07-22
PL306291A1 (en) 1995-06-26
YU73494A (sh) 1997-03-07
CA2138101A1 (en) 1995-06-16
NZ270140A (en) 1996-05-28
BR9404991A (pt) 1995-08-08
GR3034909T3 (en) 2001-02-28
US5618714A (en) 1997-04-08
NO944846L (no) 1995-06-16
DK0658626T3 (da) 2000-10-16
ATE196165T1 (de) 2000-09-15
JP3662614B2 (ja) 2005-06-22
CN1107887A (zh) 1995-09-06
NO944846D0 (no) 1994-12-14
ES2149244T3 (es) 2000-11-01
PL176381B1 (pl) 1999-05-31
SI0658626T1 (en) 2001-02-28
PT658626E (pt) 2001-01-31
RU94043769A (ru) 1997-03-27
ZA949981B (en) 1996-06-14
CO4340654A1 (es) 1996-07-30

Similar Documents

Publication Publication Date Title
KR920010871B1 (ko) 동물세포의 배양
US5976833A (en) Method for animal cell culture
US5510261A (en) Method of controlling the degradation of glycoprotein oligosaccharides produced by cultured Chinese hamster ovary cells
AU2008345231B2 (en) Cell culture processes
Avgerinos et al. Spin filter perfusion system for high density cell culture: production of recombinant urinary type plasminogen activator in CHO cells
FI106385B (sv) Förfaranden för att producera protein C
Chen et al. Temperature shift as a process optimization step for the production of pro-urokinase by a recombinant Chinese hamster ovary cell line in high-density perfusion culture
US9212214B2 (en) Methods of increasing the expression yield of vitamin K-dependent proteins
Tharmalingam et al. High yields of monomeric recombinant β‐interferon from macroporous microcarrier cultures under hypothermic conditions
Roychoudhury et al. Synthesis, regulation and production of urokinase using mammalian cell culture: a comprehensive review
EP0756003B1 (en) Method of culturing animal cells
KR100267720B1 (ko) 사람 글루타민 합성효소 유전자를 포함하는 발현벡터 및 이를 이용하여 동물세포에서 에리트로포이에틴을 고수율로 생산하는 방법
CN100392079C (zh) 蛋白c或活化的蛋白c-样分子
AU2014274601B2 (en) Cell Culture Processes
US10301611B2 (en) Process for refolding recombinant chymotrypsin
Gudzenko et al. Thermal stability of Cryptococcus albidus α-L-rhamnosidase
Pak Expression of autocrine growth factors in Chinese Hamster ovary (CHO) cells.
WO2016198499A1 (en) IMPROVED METHOD FOR PRODUCTION OF γ-CARBOXYLATED POLYPEPTIDES
JPS6336782A (ja) ヒト組織プラスミノゲン活性化因子の産生法
Khaparde et al. Session: Biological Engineering ChemCon’04 Mumbai